In-Jae Oh1, Hye-Eun Kim2, Sang-Yun Song3, Kook-Joo Na3, Kyu-Sik Kim1, Young-Chul Kim1, Seung-Won Lee2. 1. Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital Jeonnam, Korea; Department of Internal Medicine, Chonnam National University Medical School Gwangju, Korea. 2. Department of Anatomy, Chonnam National University Medical School Gwangju, Korea; Center for Creative Biomedical Scientists, Chonnam National University Gwangju, Korea. 3. Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital Jeonnam, Korea; Department of Thoracic & Cardiovascular Surgery, Chonnam National University Medical School Gwangju, Korea.
Abstract
BACKGROUND: We selected glutathione peroxidase 3 (GPx3) as a specific candidate that is down regulated in patients with lung cancer. In this study, we examined the diagnostic value of serum GPx3, which is an extracellular protein and readily detectable in blood. METHODS: We collected serum samples from 342 patients with lung cancer and 126 controls (normal healthy people and patients with benign diseases or other malignancies). We measured serum GPx3 levels using the enzyme-linked immunosorbent assay. RESULTS: Mean serum GPx3 levels were significantly lower in the patient group compared with the control group (10.1 ± 5.0 μg/mL vs. 13.0 ± 5.8 μg/mL, P < 0.001). In addition, mean serum GPx3 levels tended to be lower in the patients without metastasis compared with those with metastasis (9.6 ± 4.5 μg/mL vs. 10.7 ± 5.7 μg/mL, P = 0.051). Furthermore, mean serum GPx3 levels had a significant difference according to initial treatments (P < 0.001). In other words, mean serum GPx3 levels were significantly lower in the surgery group (8.2 ± 4.1 μg/mL) compared with the concurrent chemoradiotherapy (11.5 ± 4.6 μg/mL, P < 0.001), chemotherapy (10.7 ± 5.6 μg/mL, P < 0.001), and supportive care groups (10.9 ± 4.8 μg/mL, P = 0.002). CONCLUSION: Our results showed that serum GPx3 levels were significantly lower in the patients who underwent surgery, which indicates that the serum may have diagnostic value in patients at an operable stage of lung cancer, rather than those at a locally advanced or metastatic stage.
BACKGROUND: We selected glutathione peroxidase 3 (GPx3) as a specific candidate that is down regulated in patients with lung cancer. In this study, we examined the diagnostic value of serum GPx3, which is an extracellular protein and readily detectable in blood. METHODS: We collected serum samples from 342 patients with lung cancer and 126 controls (normal healthy people and patients with benign diseases or other malignancies). We measured serum GPx3 levels using the enzyme-linked immunosorbent assay. RESULTS: Mean serum GPx3 levels were significantly lower in the patient group compared with the control group (10.1 ± 5.0 μg/mL vs. 13.0 ± 5.8 μg/mL, P < 0.001). In addition, mean serum GPx3 levels tended to be lower in the patients without metastasis compared with those with metastasis (9.6 ± 4.5 μg/mL vs. 10.7 ± 5.7 μg/mL, P = 0.051). Furthermore, mean serum GPx3 levels had a significant difference according to initial treatments (P < 0.001). In other words, mean serum GPx3 levels were significantly lower in the surgery group (8.2 ± 4.1 μg/mL) compared with the concurrent chemoradiotherapy (11.5 ± 4.6 μg/mL, P < 0.001), chemotherapy (10.7 ± 5.6 μg/mL, P < 0.001), and supportive care groups (10.9 ± 4.8 μg/mL, P = 0.002). CONCLUSION: Our results showed that serum GPx3 levels were significantly lower in the patients who underwent surgery, which indicates that the serum may have diagnostic value in patients at an operable stage of lung cancer, rather than those at a locally advanced or metastatic stage.
Authors: Baishen Chen; Xi Rao; Michael G House; Kenneth P Nephew; Kevin J Cullen; Zhongmin Guo Journal: Cancer Lett Date: 2011-10-01 Impact factor: 8.679
Authors: D Ratnasinghe; J A Tangrea; M R Forman; T Hartman; E W Gunter; Y L Qiao; S X Yao; M J Barett; C A Giffen; Y Erozan; M S Tockman; P R Taylor Journal: Cancer Causes Control Date: 2000-02 Impact factor: 2.506
Authors: Yan P Yu; Guoying Yu; George Tseng; Kathleen Cieply; Joel Nelson; Marie Defrances; Reza Zarnegar; George Michalopoulos; Jian-Hua Luo Journal: Cancer Res Date: 2007-09-01 Impact factor: 12.701